Aethlon Medical Inc (AEMD)

[ANESRI]

From yesterday'S PR -

"As a result of crossing the IDE approval threshold, we opened the door to advance relationships with medical institutes that have clinical interest in expanding Hemopurifier® indications to include various forms of cancer."

"When we initiated our first cancer research activities, we were making two intuitive yet forward-looking bets. The first was that exosomes would emerge to become a vital therapeutic target. The second was a belief that novel immunotherapies would rethink the landscape for treating cancer. Today, tumor-secreted exosomes are well-documented therapeutic targets and cancer immunotherapies are expected to take center stage in the cancer treatment arena. There is growing hope that the marriage of traditional cancer therapies with next-generation immunotherapies may someday allow cancer to become a manageable condition much like HIV-infection is managed through a cocktail of treatment mechanisms. At Aethlon Medical, our role is to provide the oncology community with a therapeutic tool that counters the immunosuppressive impact of exosomes without adding drug toxicity to companion cancer therapies."'